Small Molecules
27 February 2013
Ampio Pharmaceuticals Initiates Clinical Trial of Optina™ in Diabetic Macular Edema (DME): First Patient Dosed27 February 2013
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-10226 February 2013
Bayer’s Stivarga (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors26 February 2013
AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation26 February 2013
Boston Therapeutics Reports Positive Phase ll Clinical Trial Results of PAZ320 in Patients With Type 2 Diabetes26 February 2013
Psyadon Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 3 Study of Ecopipam for the Orphan Indication Lesch-Nyhan Disease25 February 2013
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain24 February 2013
Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status24 February 2013
VIVUS Receives Decision Regarding Qsiva Appeal24 February 2013
Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.24 February 2013
Janssen Files First Regulatory Application for Simeprevir (TMC435) for the Treatment of Genotype 1 Hepatitis C Patients in Japan21 February 2013
New findings from two studies support substantial benefit of Pradaxa for prevention of recurrent deep vein thrombosis and pulmonary embolism21 February 2013
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Trial21 February 2013
Neurovance Receives Notice of Allowance for Composition of Matter Patent and Initiates Clinical Trial of New SR Formulation of EB-102021 February 2013
Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia21 February 2013
Alexza Receives Marketing Authorization for ADASUVE® (Staccato Loxapine) in the European Union19 February 2013
Edison Pharmaceuticals & Bambino Gesu Children’s Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial19 February 2013
Data Demonstrating the Safety and Efficacy of Chimerix’s Antiviral CMX001 Presented at BMT Tandem Meetings19 February 2013
GSK and Theravance Announce FDA Acceptance of New Drug Application (NDA) Submission in the US for ANORO ELLIPTA(TM) for COPD19 February 2013
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease19 February 2013
Gilead’s Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 StudyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports